Clinical trial
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
NCT04166474
Study timeline
Study start (actual)2021-11-18Date precision: day
Registry last updated2024-08-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Hivunresolved
Tuberculosisunresolved
Interventions
DolutegravirDRUG · verified · RxNorm: dolutegravir
Sponsors & collaborators
Helen Reynoldslead sponsor
Infectious Disease Institute, Kampala, Ugandacollaborator
Desmond Tutu HIV Centrecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04166474 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.